Background-Omega-3 fatty acid (n-3 FA) blood levels and intake have been inversely associated with risk for sudden cardiac death, but their relationship with all-cause mortality is unclear. The purpose of this study was to determine the extent to which baseline blood n-3 FA levels are associated with reduced risk for all-cause mortality in patients with stable coronary heart disease. Methods and Results-The Heart and Soul study used a prospective cohort design with a median follow-up of 5.9 years.
M ultiple lines of evidence (epidemiological, mechanistic, and clinical trial) support the view that the long-chain omega-3 fatty acids (n-3 FAs) eicosapentaenoic and docosahexaenoic acids (EPA and DHA, respectively) reduce the risk for death from coronary heart disease (CHD). 1,2 N-3 FAs are polyunsaturated fats that must be obtained from the diet. Lower red blood cell levels of EPAϩDHA have been found in patients with acute coronary syndrome 3 and primary cardiac arrest. 4 In prospective studies, n-3 FA levels were also independently associated with risk for CHD events and CHD mortality. 5, 6 Given this prior research, red blood cell levels of EPAϩDHA have been proposed as a marker for cardiovascular health and risk of fatal CHD. 7 Two randomized controlled trials of n-3 FA supplementation, one in survivors of acute myocardial infarction 8 and the other in patients with heart failure, 9 found that treatment significantly reduced all-cause mortality. However, observational studies based on estimated fish or n-3 FA intakes have yielded conflicting results regarding overall mortality, 10 -19 but these were not conducted in patients with established CHD in whom an n-3 FA deficit would be expected to have a significant impact on health. In addition, the use of diet questionnaires instead of biomarkers to assess n-3 FA exposure may partly explain the failure to observe significant associations in some studies.
In the present study, we measured blood levels of EPAϩDHA and assessed vital status in a prospective cohort of 956 ethnically diverse adults with CHD. We hypothesized that higher levels of EPAϩDHA would be associated with decreased mortality after adjusting for standard cardiovascular risk factors, demographics, and lifestyle factors.
WHAT IS KNOWN
• Populations that report higher intakes of long-chain omega-3 fatty acids (eicosapentaenoic and docosahexaenoic acids) have lower rates of heart disease death than those with lower intakes. • Supplementation with omega-3 fatty acids has reduced risk for total mortality in high-risk populations. • Blood levels of omega-3 fatty acids are reliable surrogates of tissue levels, but are only moderately correlated with dietary intakes of these fatty acids.
WHAT THE STUDY ADDS
• Patients with coronary heart disease with aboveaverage blood levels of omega-3 fatty acids are at lower risk for death from any cause than patients with lower levels. • A reduced blood omega-3 level is an independent risk marker for death from any cause in patients with stable coronary heart disease.
Methods

Participants
As described previously, 20 The study protocol was approved by the appropriate institutional review boards, and all participants provided written informed consent. Participants underwent a day-long baseline study appointment that included a medical history interview, a physical examination, and a comprehensive health status questionnaire. Before the baseline visit, study participants refrained from smoking for 5 hours, did not take aspirin for 1 week, and completed an overnight 12-hour fast (except for prescribed medications taken with water). Fasting venous blood samples were drawn, and serum and whole blood were frozen at Ϫ70°C. Participants for whom frozen blood was not available (nϭ37) were excluded and 5 subjects were lost to follow up. For consistency across types of analyses, all subjects missing on 1 or more confounding variables were eliminated (nϭ26), resulting in a sample size of 956 participants for this study. Mortality was similar between the 68 excluded patients and the 956 in the analysis (22% and 25%, respectively; Pϭ0.65). The excluded patients were also similar in age, sex, and race (minimum Pϭ0.17). Of note, the excluded patients were more likely to be from a Veterans Affairs Medical Center (Pϭ0.002) because we started our recruitment at the VA and did not have the blood draw protocol up and running for the first 35 patients who enrolled.
Predictors: EPA؉DHA Levels
Levels of EPAϩDHA in whole blood were measured by capillary gas chromatography as previously described 21 and are expressed as a percent of total blood fatty acids. Two erythrocyte control pools were included with each batch to monitor analytic performance. The intra-assay coefficient of variation in the control sample included in each batch was 5.5% for EPAϩDHA.
Outcomes: Vital Status
Annual telephone interviews were conducted with participants or their proxies to ask about vital status. All reported deaths were confirmed by review of death certificates, which determined event date for analyses. Censoring was defined as time to death or last follow-up.
Other Variables
Age, sex, ethnicity, medical history, household income, education level, and history of tobacco use were collected by self-report on baseline questionnaires. Household income and education level were included as measures of socioeconomic status, which affects dietary intake of n-3 FAs. 21 Medical centers were grouped as Veterans Affairs, university medical center, or health clinic. Categories for ethnicity were Hispanic, Asian, white, African American, or other. Annual household income was grouped as Ͻ$10K, $10K to Ͻ$20K, $20K to Ͻ$40K, and Ͼ$40K. Education level was divided into 4 categories: Ͻ12th grade, high school graduate or equivalent, some college, or completing a 4-year degree or higher. Body mass index was calculated from height and weight at the baseline visit. During their baseline visit, participants were asked how physically active they had been the previous month. Participants selected "not at all," "a little," "fairly," "quite," "very," or "extremely" active; "fairly and quite" were grouped together as were "very or extremely." All current medications were collected by inspection of prescriptions brought to the baseline visit. Fasting serum samples were used to measure total cholesterol, high-density lipoprotein cholesterol, triglycerides, high-sensitivity C-reactive protein, interleukin-6, and tumor necrosis factor ␣-␣, as previously reported. 22 All patients underwent complete resting 2-dimensional echocardiography and Doppler examination using an Acuson Sequoia ultrasound system (Siemens Medical Solutions, Mountain View, Calif) with a 3.5-MHz transducer. Standard parasternal short-axis and apical 2-and 4-chamber views were obtained and planimetered to determine end-diastolic and end-systolic volumes. The left ventricular ejection fraction (LVEF) was calculated as (end-diastolic volumeϪend-systolic volume)/end-diastolic volume.
Statistical Analyses
Differences in baseline characteristics were evaluated using Wilcoxon rank-sum test and 2 test for continuous and categorical data, respectively. To test the association between blood EPAϩDHA levels and all-cause mortality, Kaplan-Meier, and Cox proportional hazards regression models were developed. Unadjusted differences in Kaplan-Meier estimated survival functions were tested using the log-rank statistic. Log-transformed confidence intervals were calculated for the 75th survival percentile using the method developed by Brookmeyer and Crowley. 23 The unadjusted model was followed by the sequential addition of potential confounders, including demographics, socioeconomic status, smoking, LVEF, history of hypertension, diabetes, body mass index, statin and aspirin use, and physical activity. The final model involved the addition of potential mediators, including lipids and inflammatory markers.
Nonlinear relationships between confounding variables and outcome were examined using Martingale residuals that estimate the excess number of events over time in a Cox model and can reveal the correct functional form. Linear and logarithmic forms of the continuous covariates were compared. 24, 25 Quadratic relations were inspected by testing the higher-order term of the covariates. This resulted in C-reactive protein, triglycerides, and total cholesterol being natural log-transformed, whereas a quadratic term was added to age. Standardized score residuals confirmed the proportional hazards assumption. Deviance residuals were used to identify outliers, and their chromatographs were verified for EPA and DHA levels.
Last, to evaluate possible confounding by other fatty acids, the following fatty acids were substituted for EPAϩDHA in a univariate Cox model:C18:1 trans, C18:2n6 trans, linoleic acid, arachidonic acid, ␣-linolenic acid, docosapenteonoic acid, and EPA and DHA individually). If a possible confounding fatty acid had a significant univariate relationship, it was examined in the sequentially-adjusted models described above. A probability value of Ͻ0.05 was used to ascribe statistical significance. Analyses were performed using SAS software (version 9.2; SAS Institute Inc, Cary, NC).
Results
The final cohort of 956 patients comprised 396 from VA Medical Centers, 232 from public health clinics, and 328 from the UCSF Medical Center. Median follow-up was 5.9 years (interquartile range, 4.5 to 6.0 years), during which 237 (25%) participants died. The whole-blood EPAϩDHA was greater in those who survived than in those who did not (geometric means, 3.8% versus 3.6%, Pϭ0.05). To evaluate a dose response in EPAϩDHA, the unadjusted death rates were examined by quartiles. There was no significant difference between quartile 1 (26.4%) and quartile 2 (29.7%) of EPAϩDHA (Pϭ0.42, 2-proportion Z-test), nor between quartile 3 (20.1%) and quartile 4 (22.9%) (Pϭ0.45). In other words, death rates exhibited a step function, not a gradient, and therefore the 2 lower and upper quartiles were each combined (difference Pϭ0.02).
All 956 participants were therefore grouped by the median EPAϩDHA level (at or above versus below 3.6%; Table 1 ). Compared with participants below the median, those at or above the median were older, less likely to be African American or Hispanic, and more likely to be Asian and of higher socioeconomic status. Participants above the median also had a more favorable cardiovascular risk profile (eg, higher HDL cholesterol and lower total cholesterol, triglyceride, C-reactive protein, and interleukin-6 levels; a lower prevalence of smoking and diabetes; and were more likely to be very or extremely physically active). The hazard ratio for those at or above the median level (adjusted for age, sex, ethnicity, and medical center) was reduced by 39% for all-cause deaths (PϽ0.0001, Table 2 , Model 1). After further adjustment for potential confounders and mediators, the relative risk reduction ranged from 26% to 31%, and the effect remained significant (PϽ0.05) throughout all covariate models ( Table 2 , Models 2 to 4). In the fully adjusted model and independent of EPAϩDHA, other highly significant relations with total mortality were observed for increasing age and interleukin-6 (directly) and higher LVEF and statin use (inversely; Table 3 ). Using median blood EPAϩDHA categories, Kaplan-Meier-estimated survival curves demonstrated a significant difference in time to death ( Figure; log-rank Pϭ0.02). Time to 25% mortality was 5.1 years (95% confidence interval, 4.7-6.2) and 6.3 years (95% confidence interval, 5.9 -6.9) in those participants whose blood EPAϩDHA were below and at or above the median, respectively.
To determine if other FAs could be influencing the differences in mortality associated with levels of EPAϩDHA, we substituted several other fatty acids for EPAϩDHA in a univariate Cox model. EPA and DHA individually had significant inverse associations with all-causes mortality; additionally C18:1 trans and C18:2n6 trans had significant direct associations ( Table 4 ). Each of the individual fatty acids remained significant when adjusted for demographics included in Model 1. Only EPA was significant after further adjustment for LVEF, risk markers, and socioeconomic factors found in Model 2. However, the effect of EPA was attenuated when lipids from Model 3 were included. Both trans fats (the only other fatty acids that showed univariate relations with total mortality) and their interaction terms with the median EPAϩDHA were included in the final Model 4 to test for moderating relationships. The median level of EPAϩDHA (at or above versus below 3.6%) remained significant (Pϭ0.04), but the trans fats did not (minimum Pϭ0. 22 ).
Discussion
In patients with stable CHD, we found that higher baseline blood levels of EPAϩDHA were associated with an increase in survival time. These findings were independent of traditional cardiovascular risk factors, serum lipids, and of inflammatory markers, and they harmonize with our recent obser- vation that in this same cohort, the rate of telomeric shortening (a surrogate for cellular aging) was inversely and independently related to blood EPAϩDHA levels. 26 Although it was not the purpose of this study to formally evaluate the prognostic value of blood n-3 FA levels with respect to total mortality, we were able to gain some insights that may be used in future studies with that goal. Based on a review of the literature, a red blood cell (RBC) EPAϩDHA level of 4% had originally been proposed, 7, 27 as segregating intermediate from high-risk patients. This value found some support in a subsequent cross-sectional analysis. 3 In the current study, RBCs were not available, only whole blood. Fortunately, with our method there is a very strong correlation (Rϭ0.96, PϽ0.0001; unpublished findings) between the EPAϩDHA content of RBCs and whole blood, and both metrics have been associated with risk of CHD events, including primary cardiac arrest 4 and sudden cardiac death. 6 Converting the median whole blood EPAϩDHA value observed in our study of 3.6% to the RBC-based equivalent gave an n-3 index median value of 4.6%, not far from the originally proposed 4%. Although these results suggest that there may be a threshold above which little additional risk reduction may be expected, a very low risk value (previously proposed as 8% 7 ) could not be evaluated in the present study, owing to the very few patients who had levels this high.
The relations between the intake of long-chain n-3 FA and all-cause mortality (as opposed to cardiovascular) have been described in many different study populations but are inconsistent. Based on estimated fish or n-3 consumption, 4 studies found significant inverse associations with mortality, 10 -13 whereas 8 studies did not. 10,11,14 -19 A 5-year follow-up of 415 Swedish CHD patients 28 reported a trend (Pϭ0.06) for reduced total mortality associated with increasing fish intake but no relations with CHD mortality (Pϭ0.73). Positive findings on total mortality and n-3 FAs from prospective cohort studies from China, 29 Japan, 11 and Korea 30 (regions where CHD is not the major cause of death) harmonize with our findings. In a recent report from Norway, elderly, hospitalized patients (mean age, 82 years) with serum phospholipid EPA levels in the lowest quartile were at twice the risk for death over 3 years compared with those subjects in the 3 higher quartiles. 31 Higher RBC EPA and DHA levels in centenarians compared with elderly (61 to 99 years of age) control subjects 32 also support the beneficial effect of higher n-3 levels on total mortality. Anderson et al 33 reported that reduced plasma EPA levels were associated with greater 20-year mortality in a mixed ethnic population in London. Finally, in a meta-analysis of the effects of dietary and pharmacological treatments for dyslipidemia, total mortality was reduced by only 2 agents: n-3 fatty acids and statins. 34 Some of the conflicting findings from other prospective cohort studies may stem from the use of dietary questionnaires, which may not provide accurate estimates of n-3 FA exposure. 35 Even if intake could be precisely determined, direct measurement of blood levels of EPAϩDHA provides information on interindividual differences in FA metabolism that diet assessments cannot capture. We recently reported that nonfried fish consumption explained only 37% of the variability in the n-3 index, 36 and when combined with information on fish oil supplementation, only 47% of the variation was explained. 37 In addition to dietary intake, it has been suggested that genetic factors may play a role in establishing blood EPA and DHA content. One single nucleotide polymorphism (rs3834458) in the promoter region of the gene encoding ␦-6 desaturase (the enzyme that controls the conversion of ␣-linolenic acid to EPA) is associated with lower plasma and adipose EPA levels. 38 This polymorphism explains about 5% of the variability in plasma phospholipid EPA levels. 39 Because only about half of the variability in the blood n-3 FA levels can be explained by known factors, the estimation of n-3 FA exposure is best performed by direct blood measurement. Increased n-3 FA levels may decrease mortality through a variety of mechanisms. In prior studies, increased intakes of n-3 FAs have been reported to reduce heart rate, 40 inhibit platelet function, 41 and, at high doses, to reduce serum triglyceride 2, 42 and inflammatory marker levels. 43 These factors may contribute to an observed increase in plaque stability 44 and to a reduced risk for arrhythmias 45 and death from heart failure. 9 These FAs also modulate a wide variety of fundamental physiological functions. At the cellular level, they affect cell signaling, alter membrane composition, 46 and modulate the behavior of ion channels. This can lead to changes in several biological systems, for example, alterations in immune function via interleukin signaling 47 and prevention of apoptosis. 48 n-3 FAs are also converted into a variety of eicosanoids, such as prostaglandins, leukotrienes, prostacyclins, thromboxanes, and neuroprotectins. These substances, in turn, mediate inflammation, vasoconstriction, and platelet aggregation. 49 In our model 4, adjustment for inflammatory biomarkers attenuated (but did not eliminate) the association between EPAϩDHA levels and total mortality, suggesting the beneficial effects of n-3 fatty acids may be partially mediated by a reduction in systemic inflammation. 50 Our findings suggest that testing for blood EPAϩDHA levels may have clinical utility. Unlike several other risk factors that cannot be easily modified, the level of EPAϩDHA in the blood can be raised by increased consumption of these fatty acids in either oily fish (salmon, mackerel, herring, sardines, albacore tuna, etc) or in fish oil supplements. Both approaches are safe and inexpensive, and, importantly, have been shown to reduce total mortality in randomized trials. 8, 9, 51 There are several strengths of this study, including a large and rigorously defined sample, detailed FA analysis, the inclusion of plasma lipid and inflammatory covariates, a racially diverse sample, and an unambiguous end point. There were also several limitations. This was an observational study and thus unmeasured confounding factors may have contributed to our findings. The cohort was mostly older men, all with known CHD, and thus our results may not be generalizable to younger or female patients, or those without CHD. In addition, we measured blood levels of n-3 FAs at one point in time, and levels may have fluctuated during the follow-up period. Finally, without detailed dietary analyses, we were unable to determine the extent to which low n-3 FA intakes (versus differences in metabolism) were the cause of the low EPAϩDHA in those at highest risk for death, although as noted above, only about half of the variability in this marker can be explained by dietary differences.
Conclusion
A reduced blood EPAϩDHA level is independently related to risk for death in patients with CHD. These findings suggest that EPAϩDHA tissue levels may be playing an optimizing role in normal cellular metabolism, which, if not provided, leads to premature death. Further studies are needed in larger and more diverse populations to more clearly define the utility of blood EPAϩDHA in risk prediction and to determine risk threshold levels over a wider range of values.
